Immuno-Oncology | Specialty

Historic Perspective on Recurrent HNSCC

December 22nd 2016

Historic Perspective on Systemic Therapy for Advanced HNSCC

December 22nd 2016

Multimodality Treatment for HNSCC

December 22nd 2016

Risk Stratification for HNSCC

December 22nd 2016

Biology of Head and Neck Squamous Cell Cancer (HNSCC)

December 22nd 2016

The Future of Driver Mutations in NSCLC

December 22nd 2016

Practical Experience With Dabrafenib/Trametinib in NCSLC

December 22nd 2016

Targeted Approaches in NSCLC: Lessons from Melanoma

December 22nd 2016

Patient Selection in BRAF-Mutant NSCLC

December 22nd 2016

The Evolving Mutational Landscape in NSCLC

December 22nd 2016

NSCLC: The BRAF/MEK Combination Safety Profile

December 22nd 2016

BRAF/MEK Efficacy in BRAF-mutant NSCLC

December 22nd 2016

Role of the MAP Kinase Pathway in NSCLC

December 22nd 2016

Outcomes With Chemotherapy in BRAF-Mutant NSCLC

December 22nd 2016

Understanding the BRAF-mutated Population in NSCLC

December 22nd 2016

Current Mutation Testing in Lung Cancer

December 22nd 2016

Dr. Dadu on Treatment Approaches in Medullary Thyroid Cancer

December 22nd 2016

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches in medullary thyroid cancer.

The Future of Glioblastoma

December 21st 2016

Emerging Vaccines in Glioblastoma

December 21st 2016

Glioblastoma: The Potential Role of Immunotherapy

December 21st 2016